July 15th, 2013
Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it
has initiated a research and development collaboration on novel engineered botulinum toxins
with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years
with the aim to discover, evaluate and develop novel engineered recombinant botulinum
toxins for the treatment of serious neurologic diseases.